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6 ABSTRACT: The search for new and biocompatible materials
7 with high potential for improvement is a challenge in gene
8 delivery applications. A cell type speciﬁc vector made of elastin-
9 like recombinamer (ELR) and aptamers has been speciﬁcally
10 designed for the intracellular delivery of therapeutic material
11 for breast cancer therapy. A lysine-enriched ELR was
12 constructed and complexed with plasmid DNA to give
13 positively charged and stable polyplexes. Physical character-
14 ization of these polyplexes showed a particle size of around 140
15 nm and a zeta potential of approximately +40 mV. The
16 incorporation of MUC1-speciﬁc aptamers into the polyplexes resulted in a slight decrease in zeta potential but increased cell
17 transfection speciﬁcity for MCF-7 breast cancer cells with respect to a MUC1-negative tumor line. After showing the transfection
18 ability of this aptamer-ELR made vector facilitated mainly by macropinocytosis uptake, we demonstrated its application for
19 suicide gene therapy using a plasmid containing the gene of the toxin PAP-S. The strategy developed in this work about using
20 ELR as polymeric vector and aptamers as supplier of speciﬁcity to deliver therapeutic material into MUC1-positive breast cancer
21 cells shows promising potential and continues paving the way for ELRs in the biomedical ﬁeld.
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1. INTRODUCTION
23 Breast cancer is the principal malignancy diagnosed in women
24 in Western societies, with an estimated 230,000 new cases of
25 breast cancer being detected in the female population of the
26 USA during 2014.1 Although diﬀerent treatments, namely,
27 surgery, chemotherapy, radiation, endocrine or targeted therapy
28 using Trastuzumab, are available and all of them have been
29 shown to be eﬀective in advanced breast tumors, they improve
30 the clinical outcome but do not increase the cure rate.2 In the
31 search for alternatives, gene therapy using siRNA, toxic genes,
32 or pro-apoptotic genes, among others, has emerged as one of
33 the most promising strategies for cancer treatment.3−5
34 Moreover, the combination of gene therapy with radio- or
35 chemotherapy has shown excellent results.6−9 One successful
36 approach for gene therapy involves making use of the natural
37 killing ability of toxic agents such as ribosome-inactivating
38 proteins (RIPs). RIPs are RNA N-glycosidases that inactivate
39 by way of a site-speciﬁc deadenylation in the large rRNA of
40 eukaryotic and prokaryotic ribosomes.10,11 Speciﬁcally PAP-S
41 (Pokeweed Antiviral Protein from the seeds of Phytolacca
42 americana), which is a type I RIP, is a basic monomeric enzyme
43 of approximately 30 kDa lacking a lectin chain.12,13 Unlike type
44 II RIPs, which are able to penetrate living cells using their cell
45 recognition domain, PAP-S is not cytotoxic. For this reason, it
46 has been used as toxic element in the construction of
47 immunotoxins in diﬀerent studies.14−16
48 Advanced anticancer therapies require the development of
49 targeted biological strategies in order to maximize eﬃcacy while
50reducing toxicity. The glycoprotein MUC1 is a membrane-
51bound glycoprotein containing a variable number of PST
52domains rich in proline, serine, and threonine, with these
53residues serving as sites for post-translationally O-linked
54glycosylation.17,18MUC1 is overexpressed in epithelial tumors
55such as primary and metastatic breast cancer; thus, the O-
56glycosylation and distribution of this mucin on the cell surface
57is also known to be altered. Moreover, the overexpression of an
58under-glycosylated form of MUC1 is reported to have the
59worst prognosis for breast carcinomas.19−21 As MUC1
60glycoprotein is considered to be a marker for the poor
61prognosis of breast cancer,22 it could also be used as a
62therapeutic target. Increased cell speciﬁcity is a constant goal in
63gene therapy, and in this regard, cell-speciﬁc elements such as
64the short peptide cRGD have been linked to a nonrecombinant
65polymeric carrier in order to improve the transfection eﬃciency
66for vascular diseases.23 In addition, other targeting agents,
67including aptamers, have formed a new generation of targeting
68molecules.24 Aptamers, which are short (<100 nt of single-
69stranded DNA or RNA) oligonucleotide sequences, can bind
70small molecules, proteins, nucleic acids, and even cells and
71tissues, with high aﬃnity and selectivity.25 Indeed, aptamers
72have demonstrated low immunogenicity, good tumor pene-
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73 tration, and fast uptake and clearance, thus allowing them to be
74 used to deliver cytotoxic or labeled molecules.26 There are two
75 interesting aptamers among the list of published MUC1-speciﬁc
76 molecules: the S2.2 and 5TR1 (both are 25-base oligonucleo-
77 tide). The aptamer S2.2 binds to the core of MUC1
78 glycoprotein with relatively high aﬃnity and speciﬁcity. This
79 aptamer has been studied for diagnostic imaging and
80 radiolabeling in in vivo studies.27,28 In contrast, the aptamer
81 5TR1MUC1 is directed against the underglycosylated PST
82 domains of MUC1 and was previously designed and used for
83 molecular targeting.29,30
84 With regard to gene therapy-based strategies, nonviral
85 vectors have been widely studied over the past few years and
86 constitute the most promising alternative for overcoming the
87 immunogenicity problems inherent to viral vectors.31,32 Thus,
88 complexation of cationic polymers to the genetic material via
89 electrostatic interactions to form polyplexes has been
90 extensively used for gene transfer. PEI (polyethylenimine),
91 PEG (polyethyleneglycol), PLL (poly-L-lysine), chitosan,
92 PLGA (polylactic-coglycolic acid), and PDMAEMA (poly-
93 dimethylaminoethyl methacrylate) are some of the most widely
94 used nonviral gene-delivery vehicles.33−36 PEI, considered as
95 the gold standard of a polycationic polymer with a high density
96 of amine groups, has been proven to be an eﬃcient nonviral
97 vector due to its ability to bind to the cell surface, its high
98 uptake, and endosomal escape.37 However, depending on its
99 molecular weight and its branched or linear conﬁguration, this
100 polymer may be toxic.38
101 Among other biopolymers, elastin-like recombinamers
102 (ELRs) are protein-based polymers that are becoming
103 increasingly important in diﬀerent ﬁelds of biomedicine.39−43
104 The recent development of advanced genetic-engineering
105 techniques allows absolute control over both the architecture
106 of ELRs and their physical and chemical features, especially
107 surface charge, polydispersity, aggregation, and biocompati-
108 bility. ELR chains are randomly extended and under hydro-
109 phobic hydration below the characteristic transition temper-
110 ature (Tt), whereas above this temperature the ELR partially
111 loses its hydration to form an ordered and phase-separated
112 state44 Nano-, micro- or macro-aggregation phenomena occur
113 above this Tt depending on the architecture and composition of
114 the ELR. Consequently, changing the amino acid composition
115 to include positively charged ones results in ELRs that are more
116 stable at physiological pH and temperature. ELRs have
117 previously been used as oligolysine carriers by the Furgerson
118 group45 to deliver an EGFP−plasmid inside cells in in vitro
119 assays. However, their results showed cytotoxicity eﬀects
120 attributed to the oligolysine. Recently, we have obtained
121 promising results in the use of speciﬁcally designed ELRs joined
122 to functional peptides as agents for delivering genes in vitro.46
123 Cellular transfection can be improved by using positively
124 charged polyplexes that can interact with negatively charged
125 components on the cell membrane, such as proteoglycans and
126 cell-surface receptors.47,48 Such polyplexes can be internalized
127 by endocytosis and/or direct diﬀusion processes.49 Herein,
128 lysine enriched ELR has been speciﬁcally design to complex
129 and protect the therapeutic DNA forming stable polyplexes.
130 Moreover, to the best of our knowledge, this is the ﬁrst time
131 that cancer cell speciﬁc aptamers have been incorporated into
132 ELR polyplexes. In this work we reported the design of a
133 speciﬁc gene-delivery system for breast cancer based on ELR−
134 pDNA polyplexes with MUC1-speciﬁc aptamers adsorbed and
135 applied to suicide therapy using PAP-S expression.
2. MATERIALS AND METHODS
1362.1. Chemicals and Cell Lines. pCMVGaussia Luciferase
137was purchased from Thermo Scientiﬁc (USA). The gene of
138PAP-S50 was acquired from NZYTECH (Portugal) and
139inserted into a pCMV plasmid from Clontech (USA).
140Paraformaldehyde was purchased from Sigma-Aldrich.
141Twenty-ﬁve kDa of branched PEI, polyclonal anti-MUC1
142antibody, chloroquine, ﬁlipin, amiloride, and monodansylcada-
143verine were purchased from Sigma-Aldrich (Germany).
144Turbofect and Lipofectamine LTX were purchased from
145Thermo Scientiﬁc (USA).
146The aptamers S2.2 (5′GCAGTTGATCCTTTGGATA-
147CCCTGG′3), 5TR1 (5′GAAGTGAAAATGACAGAACACA-
148ACA′3) and thiol-modiﬁed 5TR1 (5′thiol (C6−S−S)-
149GAAGTGAAAATGACAGAACACAACA′3) were purchased
150from Metabion (Germany). Plasmid DNA was prepared
151using the Endofree Plasmid Giga Kit (Qiagen, Germany).
152Normal Human Adipose-Derived Mesenchymal Stem Cells
153(MSCs, ref R7788−115), basal medium Dulbecco’s modiﬁed
154Eagle’s medium (DMEM), fetal bovine serum (FBS),
155penicillin−streptomycin solution, trypsin−EDTA, DPBS,
156LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells,
157and Alamar Blue were supplied by Invitrogen (USA). Human
158umbilical vein endothelial cells (HUVECs cc-2517) and
159endothelial growth medium (EGM) were purchased from
160Lonza (Lonza Walker). Human foreskin ﬁbroblasts (HFF-1, ref
161SCRC-1041) were purchased from the American Type Culture
162Collection (ATCC, USA). Human breast cancer (MCF-7, ref
16386012803) and liver hepatocellular carcinoma (HepG2, ref
16485011430) cell lines were supplied by Sigma-Aldrich. Eagle’s
165minimum essential medium (EMEM), 2 mM glutamine, and
1661% NEAA were purchased from Invitrogen.
1672.2. Synthesis and Characterization of the Cationic
168ELR. The cationic ELR was created using standard molecular
169biology techniques and bacterial biosynthesis. This recombi-
170nant polymer was based on the pentapeptide Val-Pro-Gly-Xaa-
171Gly (VPGXG) present in elastin, where X is lysine: (VPGKG)
172×72. The multimeric gene was constructed using the recursive
173directional ligation method and then inserted into a modiﬁed
174version of pET25b expression vector (Novagen, Germany).51
175The polymer with a controlled length and molecular weight was
176produced in Escherichia coli BLR (DE3) strain (Stratagene,
177USA) as reported previously.51 To produce the polymer, the
178expression vector was transformed into Escherichia coli BLR
179(DE3) strain (Stratagene, USA). Various inverse transition
180cycles (ITC) were performed to purify the expressed
181polymer.51 Endotoxins were removed from the ELR by way
182of additional NaCl and NaOH treatments.52 Finally, the
183polymer was dialyzed against deionized water and freeze-dried.
184The expected molecular weight and number of amino acids was
18532 368 Da and 367 amino acids, respectively.
186The ELR was characterized by sodium dodecyl sulfate
187polyacrylamide gel electrophoresis (SDS-PAGE), amino-acid
188composition analysis, mass spectrometry (MALDI-TOF),
189proton nuclear magnetic resonance analysis (1H NMR), and
190dynamic light scattering (DLS). Endotoxin levels were
191measured using the Endosafe-PTS test (Charles River, USA).
192Samples for SDS-PAGE, MALDI-TOF, and DLS were
193prepared at 1 mg/mL in ultrapure water. For SDS-PAGE, 20
194μL of solution with 5 μL of loading buﬀer was loaded on a
195polyacrylamide gel. For DLS, polymer solution was ﬁltered
196before measurement using 0.45 μm PVDF syringe ﬁlter.
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197 For amino acid analysis after addition of a known quantity of
198 α-aminobutyric acid as internal pattern, the polymer sample
199 was hydrolyzed (6 M HCl, 1% phenol, and 2.5 h at 155 °C)
200 and evaporated. The powder was resuspended in 1 mL of 20
201 mM HCl and a 1/10 dissolution was prepared. The
202 quantiﬁcation of the less represented amino acids was made
203 from the most concentrated sample and the quantiﬁcation of
204 the most represented amino acids from the 1/10 dissolution.
205 For 1H NMR, 10 mg of polymer was solved in 600 μL of
206 (CD3)2SO.
207 2.3. Preparation and Nomenclature of ELR Com-
208 plexes. To prepare the polyplexes, the ELR was dissolved in
209 ultrapure water to a concentration of 1 mg/mL, and they were
210 left at 4 °C overnight. Complexes were formed in aqueous
211 solution by mixing the pDNA with the ELR solution in the
212 appropriate N/P ratios, where N corresponds to the number of
213 amine groups from the polymer and P to the phosphate groups
214 from the plasmid DNA. The mixtures were vortexed at 25 °C
215 for 1 min and incubated at 25 °C for 30 min for nanocomplex
216 formation. For experiments involving polyplexes and aptamers,
217 a solution of each aptamer (S2.2 or 5TR1) in ultrapure water
218 was added to the ELR/pDNA polyplex and the mixture left for
219 a further 30 min at room temperature. The complexes were
220 formed and designated according to the diﬀerent N/P/Papt
221 ratios, where Papt corresponds to the number of phosphate
222 groups in the aptamers, maintaining the N/P ratio constant and
223 increasing Papt by adding more aptamer.
224 2.3.1. Formation of ELR−Aptamer Polyplexes Conjugated
225 with Au Nanoparticles. ELR polyplexes were formed as
226 described in section 2.3 at a 50/1/4 N/P/Papt ratio, although
227 in this case the 5′-thiol-modiﬁed 5TR1 aptamer was complexed
228 with the polyplex and incubated for 30 min at room
229 temperature. Gold nanoparticles (Sigma-Aldrich, USA) were
230 mixed with the polyplex solution to a ﬁnal concentration of 5
231 nM and incubated for 5 min at room temperature.
232 2.4. Physical Characterization of ELR−pDNA Poly-
233 plexes. 2.4.1. Calculation of Tt for the ELR in the Presence of
234 pDNA. ELR−pDNA complexes were formed at three diﬀerent
235 N/P ratios (5/1, 10/1, and 50/1). After complexation, the pH
236 was adjusted with NaOH 1 M or HCl 1 M, and dynamic light
237 scattering (DLS) measurements (Zetasizer NanoZs from
238 Malvern Instruments Ltd., UK) were performed at pH 5.0,
239 7.5, and 11.5 in the temperature range 30−65 °C in order to
240 calculate the corresponding Tt.
241 2.4.2. Gel Retardation Assay and pDNA Protection. The
242 ELR−pDNA complexes were prepared at diﬀerent N/P ratios
243 (0.5, 1, 2, 3, 5, and 10/1). For the DNA protection experiment,
244 polyplexes and pDNA were additionally treated with the
245 restriction enzyme Dpn I (Thermo Scientiﬁc, USA) for 90 min.
246 All preparations were loaded onto a 0.8% agarose gel, and
247 electrophoresis was carried out in 1× TAE buﬀer at 60 mV for
248 120 min, staining with SimplySafe (EURx, Poland). The
249 complexed pDNA was visualized by exposure to UV light in a
250 transilluminator (Vilber, Germany).
251 2.4.3. Particle Size and Zeta Potential. The particle size and
252 zeta potential of the ELR/pDNA/aptamers at diﬀerent ratios
253 were measured using the Zetasizer NanoZs at a temperature of
254 37 °C. Z-average mean (nm) and zeta potential (mV) were
255 used for data analysis. Experiments were repeated three times.
256 2.4.4. Transmission Electron Microscopy (TEM). TEM
257 measurements were performed using a JEOL JEM-1230
258 electron microscope operating at 120 kV. The polyplex
259solution was dropped onto carbon-coated copper grids and
260images recorded after drying for 4 h at 37 °C.
2612.5. Cell Culture. Human breast cancer (MCF-7) and liver
262hepatocellular carcinoma (HepG2) cell lines were maintained
263in EMEM supplemented with 10% FBS, 2 mM glutamine, 1%
264NEAA, and antibiotics (culture media) at 5% CO2 and 37 °C.
265Human mesenchymal stem cells (hMSC) and human
266ﬁbroblasts (HFF-1) were cultured in DMEM supplemented
267with 100 U·mL−1 penicillin, 0.1 mg·mL−1 streptomycin, and
26810% or 15% FBS, respectively. Human umbilical vein
269endothelial cells (HUVEC) were grown in complete
270endothelial growth medium. Cells were incubated at 37 °C
271under 5% CO2, and their medium was replaced every 2 days.
2722.6. Transfection Assays. 2.6.1. Eﬀect of Polyplex−
273Aptamer System on Cell Viability. MCF-7 and HepG2 cells
274were plated at 3 × 104 cells per cm2 and incubated overnight.
275Afterward, both cell lines were incubated with the ELR−pDNA
276polyplexes formed with 0.5 μg of pCMV-Gaussia Luciferase
277plasmid at diﬀerent ratios and 1 μg pf PEI, used as reference
278polymer, under the same conditions for 5 h in FBS-free culture
279medium. After this time, the medium was replaced with a
280medium supplemented with 10% FBS and the cells incubated
281for a further 43 h at 37 °C.
282The relative number of metabolically active cells was
283evaluated using the Alamar Blue assay according to the
284manufacturer’s guidelines. Thus, the culture was incubated in
28510% Alamar Blue solution in minimum medium for 4 h at 37
286°C and under a 5% CO2 atmosphere. Subsequently, 80 μL of
287the reduced medium was transferred to a 96-well plate.
288Untreated cells were considered to represent 100% viability.
289The ﬂuorescence intensity of test samples and controls was
290measured at an emission wavelength of 590 nm after excitation
291at 560 nm using a SpectraMax M2 microplate reader
292(Molecular Devices, USA).
2932.6.2. Analysis of Transfection Eﬃciency by Luciferase
294Expression. A total of 3 × 104 cells per cm2 of MCF-7 or
295HepG2 was seeded onto 96-well plates and grown at 37 °C, 5%
296CO2 overnight. Cells were incubated in a serum-free medium
297for 5 h in the presence of the polyplexes (ELR: pCMV Gaussia
298luciferase) at speciﬁc N/P ratios with gradually increasing Papt
299ratio for both S2.2 and 5TR1 aptamers. The medium was then
300replaced by fresh serum-containing medium, and the cells
301cultured for a further 43 h. One microgram of PEI and 3 μL of
302Lipofectamine LTX or 1 μL of Turbofect to complex the
303pDNA were used as positive control. Additional transfection
304experiments with the cells preincubated with 50:1 anti-MUC1
305for 1 h at 37 °C, and experiments with incubation of polyplexes
306in the presence of 10% of serum enriched medium for 5 h,
307replaced by a fresh one, and cultured for a total of 48 h were
308accomplished. At this point a 20 μL aliquot was removed from
309the culture medium and mixed with the luciferase substrate
310(Thermo Scientiﬁc, USA). The light produced was measured
311using a SpectraMax L luminometer (Molecular Devices, USA).
312The protein content of the lysate was determined by a Bradford
313assay using a microplate reader. Luciferase expression is given
314as relative light units (RLU) per milligram of total protein.
3152.6.3. Cell Uptake Assays. 2.6.3.1. Polyplex Internalization
316Measured by Flow Cytometry. MCF-7 was seeded at 3 × 105
317cells per well onto six-well plates and left to grow at 37 °C, 5%
318CO2 overnight. Subsequently, cells were incubated with the
319polyplexes containing ﬂuorescein-labeled pCMVGaussia luci-
320ferase (puriﬁed using LabelIT Tracker, Mirus Bio LLC, USA)
321and the 5TR1 aptamer (N/P/Papt 50:1:4) in serum-free
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322 medium for 3 h. After this time the medium was replaced, and
323 cells were harvested with 0.05% trypsin−EDTA, washed with
324 D-PBS 1× twice, ﬁxed with 4% paraformaldehyde and washed
325 again with D-PBS 1×. Flow cytometry analysis was performed
326 to assess the ﬂuorescein internalized in cells (Gallios ﬂow
327 cytometer. Beckman-Coulter).
328 2.6.3.2. Polyplex Uptake Visualized by Fluorescence. The
329 same protocol from 2.6.3.1 section was followed and an
330 additional treatment with trypan blue was performed for the Z-
331 series in order to visualize the internalized labeled polyplexes.
332 Samples for confocal, phase-contrast, epiﬂuorescence, and
333 diﬀerential interference contrast (DIC) microscopy were ﬁxed
334 in 4% paraformaldehyde for 10 min. Internalization of the
335 polyplex−aptamer into cells was analyzed using a Leica SP5
336 confocal microscope (Leica Microsystems, Heidelberg). Z-
337 series were performed with a Z-step of 0.45 μm. Fluorescein
338 ﬂuorophore and phase-contrast images were overlaid to obtain
339 a multilayer image using ImageJ (provided by NIH, version
340 1.47v).
341 Bright-ﬁeld and ﬂuorescence microscopy were performed
342 using a NIKON Eclipse Ti ﬂuorescence microscope equipped
343 with a digital camera system (Digital sight DS-2MBWc)
344 (Nikon, Japan).
345 Additionally, counterstaining of nucleus with 300 nM of
346 DAPI was performed, and a z-stack composed by four images
347 with a z focal diﬀerence of 0.2 μm was performed. Further
348 orthogonal projection of z−y planes showing the pDNA
349 nuclear collocation was accomplished.
350 2.6.4. Assessment of Internalization Pathway. The same
351 protocol as 2.6.2. Section was applied for MCF-7 cells
352 pretreated with 25 μM of chloroquine, 1 μg mL−1 of ﬁlipin,
353 5 μg mL−1 of amiloride, and 100 μM of monodansylcadaverine
354 in media without serum. After inhibitors treatment, media was
355 replaced by fresh ones containing polyplexes.
356 2.6.5. Assays of Cell Transfection by PAP Expression. MCF-
357 7, HepG2, MSC, HUVEC, and HFF-1 cells were seeded onto
358 96-well plates in a quantity of 3 × 104 cells per cm2 for tumor
359 cells and 1 × 104 cells per cm2 for primary cells, in order to
360 maintain the same levels of conﬂuence for all the cell lines and
361 allowed to grow at 37 °C, 5% CO2 overnight prior to the
362 polyplex treatment.
363 For these experiments, the polyplexes ELR−pDNA (N/P
364 50/1) and ELR−pDNA−aptamer (N/P/Papt 50/1/4) were
365 formed using the pCMV-PAP plasmid. Cells were incubated
366 with the nanocomplexes at 37 °C, 5% CO2 for 5 h. After this
367 time, the medium was replaced with fresh medium containing
368 10% FBS, and the cells incubated at 37 °C, 5% CO2 for a
369 further 43 h. Cell death was quantiﬁed using the LIVE/DEAD
370 assay following the manufacturer’s instructions and measured at
371 an emission wavelength of 620 nm after excitation at 525 nm
372 using a SpectraMax M2 microplate reader (Molecular Devices,
373 USA).
374 2.7. Statistical Analysis. The RLU/mg in transfection of
375 ELR−pDNA polyplexes was analyzed using Student’s t test. All
376 results with p < 0.05 for three independent experiments were
377 considered to be statistically signiﬁcant.
3. RESULTS
378 3.1. Synthesis and Characterization of the Cationic
379 ELR. The obtained ELR gene corresponding with the amino
380 acid sequence MESLLP (VPGKG)72V where the pentapeptide
381 VPGKG is repeated 72 times, was corroborated by gene
382 sequencing. The main property of this polymer is its high
383number of lysine amino acids, which confer it a positive charge,
384together with its temperature- and pH-responsive behavior.
385The eﬃciency of the ELR production process was assessed by
386several physical and chemical techniques; SDS-PAGE, amino-
387acid composition analysis, MALDI-TOF, 1H NMR (Figure S1).
388The overall results displayed a high purity polymer with suitable
389chemical compositions (Figure S1). The amino-acid analysis
390showed an appropriate composition, and the diﬀerences can be
391attributed to the experimental error of the technique. As
392reﬂected in the MALDI-TOF spectrum, the experimental
393molecular weight of the ELR was 32 314.1 Da (SD: ±1.7),
394whereas the expected value was 32 368 Da. Additionally, the
395production yield of the bioprocess was 90 mg/L cell culture
396and the ﬁnal endotoxin levels were less than 10 EU/mg, which
397is adequate for in vitro transfection assays.52,53 In addition, the
398Tt of the ELR was assessed by DLS at diﬀerent pH values.
399Thus, Tt for the ELR at 10.5 μM in aqueous solution was above
40060 °C for all the pH tested.
4013.2. Physical Characterization of ELR−pDNA Poly-
402plexes. The ability of the ELR to complex pDNA was
403previously conﬁrmed by electrophoresis mobility of DNA,
404where the pDNA was fully retained from the N/P ratio of 2/1
405(Figure S2A). Additionally, the stability of the complex in the
406presence of endonuclease restriction enzyme was probed
407conﬁrming the ability of ELR to protect the plasmid DNA
408(Figure S2B).
4093.2.1. Transition Temperature for the ELR in the Presence
410of pDNA. Since a change of 50% in the scattering intensity is
411considered as the transition temperature,54 the Tt of ELR in
412aqueous solution was found to be close to 60−70 °C for pH
41311.5 (Figure S3).
414When ELR was complexed with pDNA, and polyplexes were
415kept at physiological conditions of pH (5−7) and temperature
416(37 °C), the complexes remained stable at all the N/P ratios
417tested (Figure S3). However, when the pH was increased to
41811.5, the presence of pDNA decreased this Tt as can be
419 f1appreciated for 50/1 ratio polyplexes (Figure 1). An increase in
420pH led to a decrease in Tt, with a striking variation in light
421scattering at pH 11.5 for all N/P ratios tested. The
422destabilization of polyplexes upon increasing the pH to 11.5
Figure 1. Normalized scattered light intensity as a function of
temperature at pH 11.5 for ELR−pDNA polyplexes at diﬀerent N/P
ratios. Arrows indicate the decreasing trend in light scattering as a
result of the presence of microaggregates with increasing temperature.
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423 became more evident in the decrease in normalized light
424 scattering to around 0.1 for all N/P ratios at lower temperatures
425 and by the presence of two size-distribution groups. One of
426 these groups corresponds to the free ELR, with a size of around
427 10−20 nm, and the other to the ELR polyplex, with a size of
428 around 100−200 nm (Figure S4). Additionally, nano- and
429 microaggregation process between polyplexes occurred. Fur-
430 thermore, an increase in the N/P ratio from 5/1 to 50/1 also
431 resulted in an increase in Tt (Figure 1). Consequently, herein
432 we provide evidence that the ELR−pDNA polyplexes are stable
433 complexes at physiological conditions in all the ratios tested,
434 and they are not inﬂuenced by the smart behavior inherent to
435 ELRs, which is present at the highest pH.
436 3.2.2. Particle Size and Zeta Potential. The size of these
f2 437 ELR−pDNA complexes was determined by DLS (Figure 2)
438 and found to range from about 100 nm at an N/P ratio of 2/1
439 to 200 nm at an N/P ratio of 5/1, with a polydispersity index
440(PdI) ranging from 0.11 to 0.20 (Figure 2A). The progressive
441increase in size and polydispersity observed was found to be
442correlated with an increase in the zeta potential up to an N/P
443ratio of 5/1. At an N/P ratio of 10/1, and despite having the
444highest PdI, the size decreased. From ratios of 10/1 to 50/1,
445the size and zeta potential remained constant at about 140 nm
446and +40 mV, respectively (Figure 2A,B). Both 5/1 (size of
447about 200 nm) and 50/1 (size of about 140 nm) ratios with a
448similar zeta potential but diﬀerent size, were chosen to assess
449the eﬀect of addition of the aptamer 5TR1 on polyplex size and
450stability by adding increasing amounts of aptamer (Papt) once
451the polyplexes had formed. A similar concentration-dependent
452eﬀect was observed at both ratios, with polyplex size increasing
453with aptamer ratio up to a value at which charge-neutralization
454occurred (50/1/49 or even earlier at 5/1/2; Figure 2E,C).
455Similarly, there was a striking increase in PdI at the N/P/Papt
Figure 2. Size, polydispersity index (PdI), and zeta potential for the ELR−pDNA polyplexes. Size (A) and zeta potential (B) for ELR−pDNA
polyplexes with an N/P ratio ranging from 2/1 to 50/1. Size (C) and zeta potential (D) for ELR−pDNA−aptamer complexes with an N/P/Papt
ratio ranging from 5/1/0 to 5/1/4. Size (E) and zeta potential (F) for ELR−pDNA−aptamer complexes with an N/P/Papt ratio ranging from 50/1/
0 to 50/1/49 (n = 3, mean ± SD).
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456 ratio corresponding to the highest size for ratios of both 5/1
457 and 50/1.
458 Additionally, a further study of polyplex surface charge was
459 performed using the zeta potential. The results of this study
460 showed a progressive increase in zeta potential from −23 mV
461 (N/P 2/1) to nearly +40 mV (N/P 10/1), with the value being
462 dependent on polymer concentration (Figure 2B). At N/P
463 ratio of 2/1 the polyplex exposes the negative charges from the
464 plasmid outward. At this low ratio, the positive charge from the
465 amine groups in the ELR seems to be strongly aﬀected by the
466 presence of phosphate groups from the pDNA and the
467 hydrophobic environment derived from the ELR polymer
468 structure. A striking increase from negative to positive values
469 was observed on going from a ratio of 2/1 to 3/1, and
470 stabilization of the surface charge was observed from 10/1 to
471 50/1 ratio. However, the addition of higher aptamer
472 concentrations initially resulted in a slight decrease in the
473 zeta potential at the low N/P ratio of 5/1, with a marked drop
474 being observed at 5/1/2 (Figure 2D). In contrast, the behavior
475 of the high ratio polyplex (50/1) showed the formation of a
476 stable positively charged particle (+40 mV) up to a ratio 50/1/
477 24, with a striking drop for the neutralization ratio 50/1/49
478 (Figure 2F).
479 3.2.3. Microscopic Analysis of Polyplexes Morphology. The
480 morphology of the polyplex was further characterized by TEM
f3 481 at a ratio of 50/1 in the absence (Figure 3A) and presence
482 (Figure 3B,C) of aptamer 5TR1 adsorbed on the polyplex at an
483 N/P/Papt ratio of 50/1/4. As can be seen from these ﬁgures,
484 the 50/1 polyplexes possess a rounded shape with a size (123.8
485 nm ± 12.1 SD) that correlates with the values obtained by DLS
486 (134.1 nm ± 2.5 SD). The pDNA appears to be located inside
487 the polyplex with the polymer surrounding it, as can be seen
488 from the diﬀerent density of the particle nucleus (Figure 3A).
489 Additionally, there appears to be no diﬀerence in the
490 morphology of these two kinds of polyplexes (Figure 3A,B).
491 A further study that showed the noncovalent absorption of the
492 aptamer to the polyplex surface was performed. To this end,
493 gold nanoparticles (5 nm) were mixed to a polyplex previously
494 made with a thiol-modiﬁed 5TR1 aptamer. The resulting
495 complexes (Figure 3C) possess a homogeneous shape and a
496 size in agreement with the TEM (Figure 3B) and DLS values
497 (Figure 2E), indicating that the gold nanoparticles mainly cover
498the surface of the polyplexes where the thiolated aptamer
499should be present.
5003.3. Transfection Assays. In light of the previous studies,
501cell viability and transfection experiments were performed in
502order to assess the suitability of the polyplex complexes for
503breast cancer gene therapy. The human cell lines used for the
504transfection assays were two tumoral cell types, namely, MCF-
5057, which is a breast cancer line overexpressing the MUC1
506glycoprotein55 as cell model for gene therapy, and HepG2, a
507hepatocarcinoma cell line with no MUC1 expression.56 Given
508the physical characterization results for the ELR−pDNA
509polyplexes discussed above, N/P ratios of 5/1 and 50/1 were
510chosen to test transfection in these human cell lines. At a 5/1
511ratio the polyplex has a size of about 200 nm and a zeta
512potential of about +30 mV, whereas at a 50/1 ratio the
513nanoparticle has a size of around 150 nm and a zeta potential of
514almost +40 mV, which confers more stability on the complex
515and should therefore increase the transfection eﬃciency.
5163.3.1. Eﬀect of the Polyplex−Aptamer System on Cell
517Viability. As a requisite for gene therapy applications, we
518evaluated the cytotoxicity of ELR−pDNA polyplexes formed
519with the innocuous pCMV-Gaussia Luciferase plasmid DNA at
520diﬀerent N/P/Papt ratios along with the aptamers S2.2 and
5215TR1 in MCF-7 and HepG2 cell lines. Since the viability levels
522at ratio of 5/1/0 were essentially 100%, only the eﬀect of the
523ratio with higher amounts of polymer and increasing quantities
524 f4of aptamer is shown (Figure 4). No polyplex-induced
525cytotoxicity was observed for any of the cell lines from a
526ratio of 50/1/0 to 50/1/49, whereas the value of cell viability
527reached nearly 150% in the breast cancer line when a higher
528proportion of aptamers was used. The viability of cells
529incubated with ELR polyplexes was compared with PEI
530polyplexes formed with the same innocuous plasmid but
531without aptamers. In our experiments, this polymer exhibited
532marked cytotoxicity in MCF-7 cells, for which the viability
533decreased to about 20%, in contrast to the results shown by
534ELR polyplexes.
5353.3.2. Luciferase Expression. Once the lack of toxicity from
536the ELR−pDNA−aptamer complexes had been conﬁrmed, it
537was necessary to assess their suitability as nonviral gene carriers
538with cancer cell line speciﬁcity conferred by the MUC1
539aptamers (5TR1 and S2.2) by using the pDNA encoding for a
540luciferase enzyme. To this end, MCF-7 (MUC1+) and HepG2
Figure 3. Transmission electronic microscopy images showing the morphology and shape of polyplexes in aqueous solution. ELR−pDNA polyplexes
at a 50/1 N/P ratio (A). ELR−pDNA−aptamer polyplexes at a 50/1/4 N/P/Papt ratio with aptamer 5TR1 (B). ELR−pDNA−aptamer polyplexes
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541 (MUC1-) cells were transfected with ELR−pDNA polyplexes
542 with both N/P ratios and including the aptamers.
543 The eﬀect of both types of polyplexes was ﬁrst studied using
544 MUC1+ cells in order to determine the best candidate. As
f5 545 shown in Figure 5A, there were important diﬀerences in
546 luciferase expression in MCF-7 cells between the two ELR
547 polyplexes. Thus, in the absence of aptamers, the 50/1 polyplex
548 was found to be more eﬃcient than the 5/1 ratio, exhibiting a
549 10-fold higher luciferase expression. However, the most marked
550 diﬀerences were observed after incorporation of the aptamers.
551 Thus, the use of diﬀerent ratios of the two aptamers with the 5/
552 1 polyplex had little eﬀect on MCF-7 transfection, whereas the
553 incorporation of both oligonucleotides into the 50/1 polyplex
554 produced an aptamer-dependent ampliﬁcation of its trans-
555 fection eﬃciency. Five diﬀerent aptamer concentrations were
556 used in the test, and in both cases, higher aptamer
557 concentrations resulted in lower transfection. At low ratios
558(N/P/Papt 50/1/4) the transfection eﬃciency increased at
559least 6-fold with respect to the nude polyplexes. However,
560transfection was also annulled when the aptamers neutralized
561their charge (50/1/49), as can be seen from Figure 2E,F. As
562regards the eﬀect of each aptamer, clear diﬀerences were also
563seen when used with the 50/1 polyplex. Thus, in the positively
564charged polyplexes (50/1/4 to 50/1/24), the aptamer 5TR1
565was found to be signiﬁcantly more eﬃcient for MCF-7
566transfection than S2.2, with a maximum increase of 2.5-fold.
567This feature was dramatically aﬀected when the aptamer
568concentration neutralized the polyplexes (50/1/49 ratio),
569thereby annulling the MUC1 speciﬁcity of the aptamers.
570In light of these results, the 50/1 polyplex was chosen for the
571remaining experiments concerning the transfection eﬀect in
572several human cell lines. In an initial study, the speciﬁcity
573induced by the presence of MUC1 in cancer lines was studied
574using the HepG2 hepatocarcinoma cell line lacking MUC1
575expression. As can be seen from Figure 5B, signiﬁcant
576diﬀerences in luciferase expression (p < 0.001) were found
577between both cell lines at this ratio, which was higher for the
578MUC1 overexpressing MCF-7 cells irrespective of the aptamer
579used. Since the best results of transfection were obtained for
58050/1/4 using 5TR1 aptamer, following studies will be focused
581on this condition. Blockade of MUC1 was performed by the
582pretreatment of cells with anti-MUC1 antibody for 1 h at 37 °C
583(Figure S5). After that time, transfection with 50/1/0 and 50/
5841/4 polyplexes was performed. The result showed a total
585inhibition of 5TR1 speciﬁcity in which the transfection levels of
58650/1/4 lowered up to 50/1/0 levels. By contrast, 50/1/0
587transfection was not aﬀected by the presence of the antibody,
588which support the evidence of the interaction between 5TR1
589and MUC1. In addition commercially available agents like PEI,
590Lipofectamine, or Turbofect were tested, and comparable levels
591of transfection were found for MCF-7 cells (Figure S6), being
592the transfection for ELR−pDNA−aptamer polyplexes at 50/1/
5934 ratio slightly higher than Turbofect and in the same order (1
594× 108 RLU mg−1 protein) than PEI. Further studies of
595transfection in the presence of 10% of serum were
596accomplished (Figure S7) as well. A reduction of gene
597expression was found for both ELR without (2.7 times) and
598with aptamer (1.6 times). The highest decrease corresponded
Figure 4. Viability of MCF-7 and HepG2 cell lines at diﬀerent N/P/
Papt ELR−pDNA ratios for aptamers S2.2 and 5TR1. Cells were
coincubated with the polyplexes, and a viability assay was performed
for all samples. Untreated cells were considered as 100% viability
control and PEI polyplexes as a reference transfection system (n = 3
independent experiments, mean ± SD). *p < 0.05, **p < 0.01.
Figure 5. Luciferase expression by pCMV-Gaussia Luciferase contained in ELR−pDNA−aptamer polyplexes. (A) Polyplexes at a 5/1 N/P ratio with
diﬀerent Papt ratios for aptamers S2.2 and 5TR1 in MCF-7 cells. (B) Polyplexes at a 50/1 N/P ratio with diﬀerent Papt ratios for aptamers S2.2 and
5TR1 in MCF-7 and HepG2 cells. Luciferase activity is expressed in RLU/mg protein lysate. The polyplex without aptamers and pDNA were used as
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599 for the polyplex alone showing the retention of the speciﬁcity
600 by the system ELR−pDNA−aptamer in the presence of serum.
601 3.3.3. Cellular Uptake of Polyplexes. The intracellular
602 uptake of these ELR−pDNA−5TR1 polyplexes was conﬁrmed
603 using various techniques. To this end, MCF-7 cells were
604 incubated with 50/1/4 polyplexes containing ﬂuorescein-
605 labeled pCMV-Gaussia Luciferase plasmid for 3 h, and the
606 resulting internalization process was initially visualized by
f6 607 ﬂuorescence microscopy (Figure 6A). Although a few
608 polyplexes were observed on the surface of the tissue culture
609 plaque, a broad distribution of nanoparticles associated with the
610 cells could also be seen. The labeled cells were then detached
611 with trypsin, in order to remove the external binding
612 ﬂuorescence signal that could interfere with the detection of
613 the intracellular polyplexes,57,58 washed with PBS and analyzed
614 by ﬂow cytometry. The results were compared with cells
615 transfected using the ﬂuorescent plasmid alone (Figure 6B).
616 The data showed a marked internalization of polyplexes of
617 85.76 ± 12.35% (mean ± SD) for all cells, in comparison with
618 cells treated with ﬂuorescein-labeled pDNA alone (1.70 ±
619 1.68%). Finally, trypan blue treated cells were visualized by
620 confocal microscopy in a z-series succession explained in Figure
621 S8 where the two focal planes conﬁrmed the presence of
622 polyplexes inside the cells (Figure 6C,D) and the likely
623 presence of ﬂuorescent plasmid inside the nucleus (indicated by
624 arrows). An additional visualization with the nucleus stained
625 with DAPI evidenced the presence of pDNA inside the nucleus
626 (Figure S9).
627 This group of assays demonstrated the cellular internalization
628 and nuclear localization of ELR−pDNA polyplexes equipped
629 with cell speciﬁcity provided by the MUC1-directed aptamers.
6303.3.4. Assessment of the Internalization Pathway. Once
631the uptake of ELR−pDNA−5TR1 polyplexes was visualized,
632the investigation of the relation between the internalization
633pathway and subsequent gene expression was accomplished.
634MCF-7 cells were treated with a variety of endocytosis
635inhibitors for 30 min at 37 °C and incubated with polyplexes
636for 5 h at 37 °C. After this time, polyplexes were removed, cells
637were incubated up to 48 h and luciferase activity was measured.
638Inhibition of Na+/H+ exchange required for macropinocytosis
639by means of amiloride decreased the luciferase expression to
64026% after transfection with ELR−pDNA−5TR1 polyplexes.
641Moreover, inhibition of caveolae-mediated endocytosis by
642ﬁlipin decreased the expression to 44%, and inhibition of
643clathrin mediated endocytosis by dansylcadaverine resulted to
644inhibit the expression to 60%. Additionally, the inhibition of
645acidiﬁcation in acidic vesicles by chloroquine did not aﬀect
646signiﬁcantly the luciferase expression. This data showed
647evidence about the primary inﬂuence of macropinocytosis
648and in a lesser extent of caveoline and clathrin-endocytosis
649 f7pathways over the gene expression (Figure 7).
6503.3.5. Eﬀect of Toxin Transfection on Human Breast
651Cancer Cells. Since we have previously shown that ELR
652polyplexes are able to reach the nucleus and express their
653genetic material in a speciﬁc manner, now polyplexes with the
654construct pCMV-PAP as pDNA and surrounded by 5TR1
655aptamer at a 50/1/4 ratio (5 μg pDNA mL−1) were used to
656transfect ﬁve diﬀerent human cell lines, namely, the tumor cell
657lines MCF-7 (MUC1+) and HepG2 (MUC1−) and three
658human primary cell types (ﬁbroblasts (HFF-1), endothelial
659(HUVEC), and mesenchymal stem cells (MSC)), to assay the
660eﬀects of polyplexes on their viability.
Figure 6. Cellular uptake of ELR−pDNA−5TR1 polyplexes with ﬂuorescein-labeled pDNA. (A) Fluorescence microscopy image of MCF-7 treated
with ELR−pDNA−5TR1 nanoparticles for 3 h (merged image of the phase-contrast and FITC channels). The scale bar corresponds to 50 μm. (B)
Flow cytometry analysis of MCF-7 cells incubated with polyplexes. Gate A, which corresponds to FITC+ cells, was set on the side-scatter vs forward-
scatter histogram. The cell count was plotted as a function of FL1, which corresponded to the FITC channel for pDNA and ELR−pDNA−5TR1
transfected cells. (C,D) Confocal microscopy images of MCF-7 containing ﬂuorescein-labeled polyplexes. Merged bright- and ﬂuorescence-ﬁeld
images of diﬀerent focal planes have been analyzed. The nuclear areas of cells with the bright green dots of polyplexes are indicated by arrows. Cells
from C and D were treated with trypan blue in order to discriminate ﬂuorescent polyplexes inside the cell. Scale bars correspond to 10 μm.
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661 The viability of the ﬁve cell lines subjected to the diﬀerent
f8 662 treatments was shown by ﬂuorescence (Figure 8). Cells
663 acquired their typical morphology in all cases. The endothelial,
664 mesenchymal, and ﬁbroblast cell cultures appeared to have the
665 lowest cell death (Figure 8, MSC, HUVEC, and HFF1
666 columns). By contrast, the human liver (Figure 8, HepG2
667 column) and breast (Figure 8, MCF-7 column) cancer cell lines
668 were both aﬀected by coincubation with the ELR/pCMV-PAP
669 polyplex containing aptamer or not. However, a higher number
670 of dead cells was found for MCF-7 in comparison with the
671 MUC1-HepG2, and an improved cytotoxic eﬀect was visualized
672 for MCF-7 cells treated with the polyplex 5TR1.
673 In order to quantify the results observed by ﬂuorescence
674 microscopy, the eﬀect of PAP-S expression was quantiﬁed in
675 terms of percentage of dead cells in both HepG2 and MCF-7
f9 676 tumor cells (Figure 9). ELR−PAP−5TR1 polyplexes were
677 found to eﬃciently kill MUC1+ breast cancer cells with a 95%
678 of death rate after incubation for 48 h. The incorporation of
679 5TR1 aptamer at the surface of the ELR−PAP polyplexes
680 resulted in a signiﬁcant increase of nearly 25% in dead MCF-7
681 cells. In contrast, no diﬀerences in percentage of dead cells for
682 polyplexes with aptamer (33%) and polyplexes alone (40%)
683 were found for the tumoral (MUC1−) HepG2 cells. Addition-
684 ally, no signiﬁcant diﬀerences were observed between any of the
685 polyplex−aptamer conditions tested in human primary cells
686 (HUVEC, MSC, and HFF-1) with levels of cell death similar to
687 those for untreated cells. These results highlight the selective
688 eﬀect of the transfected plasmid in breast cancer cells
689 presenting MUC1 in comparison with other tumor and
690 primary cells.
4. DISCUSSION
691 A variety of strategies have been applied in order to design
692 biomaterials with application in gene therapy. Herein we report
693 the design of a speciﬁc gene-delivery system for breast cancer
694 based on ELR−pDNA polyplexes and complexed with MUC1-
695 speciﬁc aptamers. The ELR used in this study was constructed
696 using recombinant techniques, thus giving them a high level of
697versatility and allowing the incorporation of positively charged
698amino acids, such as lysine in a simple manner. The main
699property of this ELR is its high number of lysines, which are
700responsible for its temperature- and pH-responsive behavior at
701physiological conditions.
702In order to verify that the designed ELR based polyplexes
703were stable despite of the ELR smart temperature-responsive
704behavior, an initial study analyzing the eﬀect of diﬀerent
705conditions of pH and temperature over the Tt was conducted.
706Most of the polymers used for transfection are positively
707charged, thus allowing them to complex with the negatively
708charged pDNA. Considering the Tt as an intrinsic characteristic
709of ELRs, this results in a double eﬀect for the polymer, namely,
710an electrostatic interaction between the polymer and pDNA via
711the lysines, which leads to polyplex formation, and the smart
712behavior of the ELR, which triggers its aggregation and
713conformational change above Tt. This Tt can be changed by
714extrinsic factors such as the addition of negatively charged
715phosphate groups. For these ELR based polyplexes, it was
716possible to observe variation in the Tt only at pH 11.5. Thus,
717the presence of negatively charged phosphates due to
718incorporation of the pDNA into the ELR triggered polyplex
719formation and, consequently, a change in the polarity of the
720polymer, decreasing the Tt at pH 11.5 (Figure 1). Additionally,
721the variation in pH and N/P ratio showed marked eﬀects on
722the Tt. Thus, a decrease in Tt occurred for all ratios when the
723pH was increased at pH 11.5 (Figure S3). The free ε-amino
724groups from the L-lysines (pKa 10.5) in the polyplex are largely
725deprotonated at this pH, thereby decreasing the net polarity of
726the complex and promoting destabilization of the polyplexes.
727The lower light scattering at lower temperatures and the
728presence of free ELR corroborated this process (Figure S4).
729Two consecutive eﬀects, namely, initial incorporation of free
730ELR to the polyplex and a consecutive drop in the scattered
731intensity as a result of a cooperative increase in the
732hydrophobicity of the polymer and aggregation into micron-
733and nanoscale particles between the ELR on the outside of the
734polyplexes, were perceived upon increasing the temperature at
735pH 11.5 (Figure 1). Similarly, an increase in Tt was observed
736upon increasing the amount of polymer. It is remarkable to
737highlight that polyplexes at physiological pH of 7.5 and 5 are
738stable due to the absence of transition by the ELR, which make
739them useful for gene delivery applications (Figure S3).
740Besides the requirement of stable polyplexes, an appropriate
741particle size is necessary to obtain positive results in cell
742transfection. Particles with a size of about 200 nm are known to
743be internalized by endocytosis.59,60 The polyplexes obtained
744ranged from 100 to 200 nm, which is appropriate for cellular
745uptake. A progressive increase in size, polydispersity, and zeta
746potential was found up to a 5/1 ratio when increasing the N/P
747ratio. From 10/1 to 50/1 signiﬁcant constant values were
748observed, thereby suggesting a higher stability of the polyplex
749compared with the previous ratios (Figure 2A,B). The inﬂuence
750of addition of the aptamer 5TR1 was evaluated with 5/1 and
75150/1 polyplex ratios: the result was a concentration-dependent
752eﬀect. Additionally, a 50/1 ratio produced more stable
753polyplexes than 5/1 ratio due to the increase in polydispersity
754and charge neutralization at higher ratios (50/1/49). The
755gradual incorporation of aptamer provided more negatively
756charged phosphates to interact with, and neutralize, the free ε-
757amino groups from L-lysines, thereby aﬀecting the charge and
758stability of the polyplex. In contrast the presence of aptamers
759did not aﬀect the shape or size of the particles (with exception
Figure 7. Luciferase expression of ELR−pDNA−5TR1 polyplexes at
50/1/4 ratio in the presence of diﬀerent inhibitors in MCF-7 cells.
Polyplexes were incubated with cells after treatment with 25 μM of
chloroquine, 1 μg/mL of ﬁlipin, 5 μg/mL of amiloride, and 100 μM of
monodansylcadaverine. The results expressed as % of control are mean
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760 of 50/1/49 ratio), which is in accordance with the DLS results
761 (Figures 2E and 3A,B). The surface charge density studied as
762 zeta potential is directly related to the stability of many colloidal
763 systems, and it is thought that a positive zeta potential should
764 favor interaction with the cell membrane.48 However, the
765 incorporation of aptamers that provide cell speciﬁcity may
766 decrease the surface charge of the polyplex. This hypothesis was
767 corroborated in the assays conducted in this work. Initially, the
768 location of the polymer on the periphery of the polyplex where
769 it exposes its positively charged ε-amino groups to the exterior
770 while maintaining a neutralized charge inside was shown from
771 N/P ratio of 3/1. The subsequent incorporation of increasing
772 amounts of aptamer resulted in a marked decrease in the
773 surface charge of the ELR−pDNA due to neutralization of the
774 system and a widespread distribution of the aptamers on the
775polyplex surface, with polyplexes at a 50/1 ratio being more
776stable than those at a 5/1 ratio. The decrease in the surface
777charge density of polyplexes at higher concentrations of
778aptamer suggests the location of these aptamers on the
779polyplex surface. By contrast, at lower ratios of aptamer the
780surface charge density of the polyplex is highly positive pointing
781the location of amino groups from polymer outward. The
782outside arrangement of amino groups favors the interaction of
783aptamers with the polyplex surface. Additionally, the presence
784of aptamers in the polyplex was supported by the visualization
785of gold nanoparticles bound to thiol-containing aptamers
786(Figure 3C) what are thought to be located on the polyplex
787surface despite of this technique does not allow to conﬁrm this
788distribution, and some may be also entrapped. The polyplexes
789obtained in this work represent an improvement with regard to
Figure 8. Representative ﬂuorescence microscopy images for MSC, HUVEC, HFF1, MCF-7, and HepG2 cells after 5 h of coincubation with
minimum medium (untreated), pDNA, ELR−pDNA (polyplex), and ELR−pDNA conjugated with 5TR1 aptamer (polyplex 5TR1) where the
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790 previous studies46 concerning the zeta potential and stability of
791 particles besides the incorporation of breast cancer cell speciﬁc
792 aptamers.
793 ELRs as naturally inspired recombinant polymers are
794 characterized by their biocompatibility in terms of lack of
795 cytotoxicity and immunogenicity. This has been assessed in
796 both in vitro and in vivo assays thus making them appropriate
797 for local and systemic administration.52,61 Similar results were
798 obtained in in vitro studies involving positively charged ELRs.41
799 In light of these ﬁndings and the physical characterization of the
800 polyplexes, their cytotoxicity with S2.2 and 5TR1 aptamers was
801 evaluated using both cancer lines. The results showed that the
802 cell viability of MCF-7 cells incubated in the presence of
803 polyplexes with diﬀerent ratios was clearly higher than 100%
804 and about 100% for HepG2 (Figure 4). A similar increase in
805 viability was previously observed in a murine myoblastoma cell
806 line,62 human breast cancer cell line,63 and mesenchymal stem
807 cells,64,65 when treated with several ELRs and, recently, when
808 C6 rat glioma cells were coincubated with ELR polyplexes,46
809 thereby demonstrating the friendly nature of these recombinant
810 polymers as well as the supplemental speciﬁcity conferred by
811 the aptamers on MUC1+ cells. In contrast, a high level of
812 cytotoxicity was found for cells treated with PEI, probably due
813 to the presence of free PEI after formation of polyplexes, which
814 disrupts the plasmatic membrane and causes necrosis.66,67
815 Although PEI is commonly used in transfection for in vitro
816 assays, it often has a strong cytotoxic eﬀect, depending on the
817 cell line, as reported elsewhere.66,68 Nowadays research is
818 focusing in decreasing this toxicity by the use of biocompatible
819 molecules such as chitosan or employing PEG as shell.69,70 In
820 contrast, previous studies with positively charged ELRs
821 incubated with blood components showed the innocuous
822 character of these polymers46 making them useful for
823 intravenous administration.
824 The next step was the evaluation of transfection level and cell
825 speciﬁcity provided by the MUC1 aptamers. Since the binding
826 speciﬁcity of both aptamers had been previously studied for
827MCF-7 cells29,71 we focused on evaluating the improvement
828provided by the aptamers with respect to the ELR−pDNA
829system. Figure 5 shows the marked improvement in trans-
830fection when using a 50/1 ratio, thus indicating that the
831physical characteristics of the nanoparticles (150 nm and +40
832mV in 50/1 versus 200 nm and +27 mV in 5/1) have a clear
833inﬂuence on transfection eﬃciency. The most striking diﬀer-
834ences were found when aptamers were incorporated, also being
835higher for a 50/1 ratio. An aptamer-dependent ampliﬁcation of
836transfection was observed for 50/1 ratio, with the lower 50/1/4
837ratio being the best of those ratios tested with comparable
838transfection levels to PEI and no toxic eﬀects. In contrast, the
839transfection values achieved in the presence of aptamers were
840lower when the latter were used in excess. This indicates that
841the positive eﬀect of aptamers is blocked, probably, according
842to the physical results (Figure 2C,D), due to the formation of
843unstable and ineﬃcient nanoparticles in which increasing
844quantities of aptamers produce, ﬁrst bigger and more
845polydisperse polyplexes and second negatively charged surfaces.
846These eﬀects over the transfection levels together with
847potential zeta values and TEM reinforce the hypothesis of
848polyplexes coated with MUC1 aptamers. Diﬀerences were also
849found between both aptamers, with the 5TR1, which targets the
850underglycosylated PST domains of MUC1, being more eﬃcient
851than S2.2, which targets the MUC1 core. In light of these
852results, the 50/1 ratio was chosen for the remaining
853transfection experiments with MCF-7 and HepG2 cell lines
854(Figure 5B). Initially, the speciﬁcity of the polyplex−aptamer
855system was evaluated using the MUC1-HepG2, with signiﬁcant
856diﬀerences in luciferase expression being found between both
857cell lines. These diﬀerences were higher for the MUC1
858overexpressing MCF-7 cells irrespective of the aptamer used.
859Consequently, the intracellular uptake of ELR−pDNA−
860aptamer polyplexes is MUC1-dependent and is more eﬃcient
861when a rational quantity of the 5TR1 aptamer is used. The
862inﬂuence of serum in transfection was also evaluated, and
863showed a reduction for the polyplex with and without aptamer
864(Figure S7). By contrast, this reduction was higher for the
865polyplex alone; this circumstance can be explained by the
866general reduction in transfection activity in polymeric
867polyplexes. Other commercially available systems such as PEI
868possess a decrease in transfection when serum is present in
869several cell lines such as ﬁbroblasts and BMSCs.72 However, it
870is remarkable to note that the speciﬁcity of the system ELR−
871pDNA−aptamer was retained despite of the presence of serum.
872This situation points the possibility of using this system for
873local or even systemic administration.
874The uptake of ELR−pDNA−5TR1 polyplexes by the
875targeted breast cancer cells was visualized by ﬂuorescence
876microscopy and quantiﬁed by ﬂow cytometry. The results
877showed marked internalization of the polyplexes with
878cytoplasmic and even nuclear location of pDNA in MUC1
879overexpressing MCF-7 cells (Figure 6 and S9). Consequently,
880the overall results allow us to establish the basis for their use as
881a plasmid carrier in gene therapy in a safe and speciﬁc manner.
882The internalization pathway was assessed by the eﬀect of
883diﬀerent inhibitors over the luciferase expression. As shown in
884Figure 7 the higher inhibitory eﬀect was observed when cells
885were pretreated with amiloride, which inhibit the Na+/H+
886exchange required for macropinocytosis. It suggests the primary
887uptake of ELR−pDNA−5TR1 polyplexes by this macro-
888pinocytosis pathway. In the same manner, polyplexes appeared
889to be internalized in a lower proportion by caveolin and
Figure 9. Targeted killing ability of ELR−PAP−5TR1 polyplexes.
Percent dead cells was calculated by ﬂuorescence quantiﬁcation. Cells
were preincubated for 5 h with minimum medium (untreated),
pCMV-PAP plasmid alone (pDNA), ELR−pDNA (polyplex), and
ELR−pDNA conjugated with aptamer 5TR1 (polyplex 5TR1).
Additional incubation under standard conditions up to 48 h was
then carried out. Mean ± standard error of three independent
experiments. A statistical analysis showed signiﬁcant diﬀerences (*p <
0.05, **p < 0.01).
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.5b00712
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
K
890 clathrin-dependent endocytosis. In fact MUC1 glycoprotein
891 uptake by macropinocytosis and clathrin-dependent pathways
892 has been previously reported,18,29 which evidence the
893 interaction of 5TR1 aptamer with the MUC1 located on the
894 cell surface. Further study with chloroquine was performed in
895 order to evaluate the eﬀect of the inhibition of endosome-
896 lysosome maturation over the gene expression. Chloroquine
897 basiﬁes the acidic vesicles and accumulates in them; this fact did
898 not involve a signiﬁcant decrease in luciferase expression.
899 Herein we can suggest the independence on acidic pH for
900 ELR−pDNA−5TR1 polyplexes endosomal escape. We hy-
901 pothesize that their interaction with MUC1 would somehow
902 favor the escape from endosome since it is known the existence
903 of high levels of MUC1-C in cytoplasm and even the nuclear
904 presence of both MUC1-C and MUC1-N.73,74
905 Since one of the major challenges in gene therapy is to use
906 the natural killer ability of cytotoxic agents or cell death
907 inducers to selectively eliminate undesirable cells,75 the
908 expression of a ribosome inactivating protein was studied in
909 this work. As described previously, PAP-S has a potent
910 cytotoxic activity but only once it reaches the cytoplasm of
911 the cell. Hence, when the plasmid containing PAP-S gene is
912 delivered inside of cells by the ELR device and expressed by the
913 cell machinery it should be able to permanently disable the
914 ribosomes by arresting the function of elongation factors EF-1
915 and EF-2 thereby causing cell death.12 Since we used a plasmid
916 codifying the PAP-S toxin and bearing in mind their potential
917 use for in vivo therapy, the transfection eﬀect of ELR−PAP−
918 5TR1 polyplexes was tested in ﬁve diﬀerent human cell lines
919 including nontumoral primary cells. The tumoral cell lines
920 MCF-7 (MUC1+) and HepG2 (MUC1−) and three human
921 primary cell types (HFF-1, HUVEC, and MSC) were chosen.
922 Fibroblasts were selected as the most representative cell type of
923 connective tissue.76 MSCs are pluripotent cells that have been
924 reported to have both stimulatory and suppressive eﬀects in
925 breast cancer.77 HUVEC allowed us to study the inﬂuence of
926 our transfection system in a model of endothelial function due
927 to the likely intravenous application of gene therapy treatments.
928 As shown in Figure 7, incubation of cells with the diﬀerent
929 treatments did not aﬀect the cell morphology for any of the
930 lines. Additionally, MCF-7 and HepG2 tumor cells were the
931 only ones clearly aﬀected by the presence of the polyplex.
932 Similarly, there was a remarkably higher sensitivity of MCF-7
933 cells to PAP-S in comparison with other nonoverexpressing
934 MUC1 cell lines. A signiﬁcant increase in the percentage of
935 death in breast cancer cells was found reaching nearly 95%
936 (Figure 9) when the 5TR1 aptamer was incorporated into the
937 polyplex thereby suggesting an eﬃcient expression of functional
938 PAP-S in the transfected cells. However, no increase was
939 observed between polyplex and polyplex−5TR1 treatment for
940 MUC1-HepG2 cells. Indeed, the lowest cytotoxic eﬀects were
941 observed when primary cells were incubated with polyplexes.
942 The fact that the eﬀects observed were similar to those for
943 untreated cells suggests a possible protective eﬀect on them. It
944 is interesting to note that the limited eﬀect on MSCs,
945 endothelial and ﬁbroblasts under conditions in which tumor
946 cells have been shown to be extensively aﬀected, is remarkable
947 as it allows us to hypothesize that either local or systemic
948 intravenous route of administration could be used without
949 damage to the bloodstream lineage. These results corroborate
950 the suitability of ELR−5TR1 aptamers for a speciﬁc suicide
951 therapy with a novel use of PAP-S as transfecting agent
952 aﬀecting only target breast cancer cells.
5. CONCLUSION
953In summary, we have developed a nonviral gene-delivery
954system comprising tailor-made elastin-like recombinamers and
955MUC1 aptamers with potential application in the treatment of
956breast cancer. When bound to plasmid DNA, this polymer is
957able to self-assemble and form a polyplex stable at physiological
958conditions and possesses a positively charged surface, a suitable
959particle size for cell internalization, and cell line speciﬁcity
960provided by the aptamers. This system selectively delivers
961plasmids bearing luciferase and PAP-S genes into tumor cells
962while protecting normal human cells. Accordingly, the use of
963this ELR−aptamer system is a promising strategy in the
964delivery of therapeutic genes of interest that target breast tumor
965cells even more considering the high potential of ELRs for
966improvement. Therefore, further research focusing on in vivo
967experiments will be conducted.
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1000thank Dr. R. Muñoz for her careful reading of the manuscript
1001and Dr. A. Frankland for English revision.
1002■ REFERENCES
(1) 1003American Cancer Society.. Cancer Facts and Figures 2014, 1−63.
(2) 1004Gonzalez-Angulo, A. M.; Morales-Vasquez, F.; Hortobagyi, G. N.
1005Overview of resistance to systemic therapy in patients with breast
1006cancer. Adv. Exp. Med. Biol. 2007, 608, 1−22.
(3) 1007Filleur, S.; Courtin, A.; Ait-Si-Ali, S.; Guglielmi, J.; Merle, C.;
1008Harel-Bellan, A.; Clezardin, P.; Cabon, F. SiRNA-mediated inhibition
1009of vascular endothelial growth factor severely limits tumor resistance to
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.5b00712
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
L
1010 antiangiogenic thrombospondin-1 and slows tumor vascularization and
1011 growth. Cancer Res. 2003, 63 (14), 3919−22.
(4)1012 Garg, H.; Salcedo, R.; Trinchieri, G.; Blumenthal, R. Improved
1013 nonviral cancer suicide gene therapy using survivin promoter-driven
1014 mutant Bax. Cancer Gene Ther. 2010, 17 (3), 155−63.
(5)1015 Li, Y.; Li, L. J.; Wang, L. J.; Zhang, Z.; Gao, N.; Liang, C. Y.;
1016 Huang, Y. D.; Han, B. Selective intra-arterial infusion of rAd-p53 with
1017 chemotherapy for advanced oral cancer: a randomized clinical trial.
1018 BMC Med. 2014, 12, 16.
(6)1019 Wang, H.; Nan, L.; Yu, D.; Agrawal, S.; Zhang, R. Antisense anti-
1020 MDM2 oligonucleotides as a novel therapeutic approach to human
1021 breast cancer: in vitro and in vivo activities and mechanisms. Clin.
1022 Cancer Res. 2001, 7 (11), 3613−24.
(7)1023 Ciardiello, F.; Caputo, R.; Troiani, T.; Borriello, G.; Kandimalla,
1024 E. R.; Agrawal, S.; Mendelsohn, J.; Bianco, A. R.; Tortora, G. Antisense
1025 oligonucleotides targeting the epidermal growth factor receptor inhibit
1026 proliferation, induce apoptosis, and cooperate with cytotoxic drugs in
1027 human cancer cell lines. Int. J. Cancer 2001, 93 (2), 172−8.
(8)1028 Vlachaki, M. T.; Chhikara, M.; Aguilar, L.; Zhu, X.; Chiu, K. J.;
1029 Woo, S.; Teh, B. S.; Thompson, T. C.; Butler, E. B.; Aguilar-Cordova,
1030 E. Enhanced therapeutic effect of multiple injections of HSV-TK +
1031 GCV gene therapy in combination with ionizing radiation in a mouse
1032 mammary tumor model. Int. J. Radiat. Oncol., Biol., Phys. 2001, 51 (4),
1033 1008−17.
(9)1034 Shim, G.; Han, S. E.; Yu, Y. H.; Lee, S.; Lee, H. Y.; Kim, K.;
1035 Kwon, I. C.; Park, T. G.; Kim, Y. B.; Choi, Y. S.; Kim, C. W.; Oh, Y. K.
1036 Trilysinoyl oleylamide-based cationic liposomes for systemic co-
1037 delivery of siRNA and an anticancer drug. J. Controlled Release 2011,
1038 155 (1), 60−6.
(10)1039 Nielsen, K.; Boston, R. S. RIBOSOME-INACTIVATING
1040 PROTEINS: A Plant Perspective. Annu. Rev. Plant Physiol. Plant Mol.
1041 Biol. 2001, 52, 785−816.
(11)1042 Girbes, T.; Ferreras, J. M.; Arias, F. J.; Stirpe, F. Description,
1043 distribution, activity and phylogenetic relationship of ribosome-
1044 inactivating proteins in plants, fungi and bacteria. Mini-Rev. Med.
1045 Chem. 2004, 4 (5), 461−76.
(12)1046 Barbieri, L.; Battelli, M. G.; Stirpe, F. Ribosome-inactivating
1047 proteins from plants. Biochim. Biophys. Acta, Rev. Biomembr. 1993,
1048 1154 (3−4), 237−82.
(13)1049 Stirpe, F.; Battelli, M. G. Ribosome-inactivating proteins:
1050 progress and problems. Cell. Mol. Life Sci. 2006, 63 (16), 1850−66.
(14)1051 Kreitman, R. J. Immunotoxins for targeted cancer therapy. AAPS
1052 J. 2006, 8 (3), E532−51.
(15)1053 Yang, W. H.; Wieczorck, M.; Allen, M. C.; Nett, T. M. Cytotoxic
1054 activity of gonadotropin-releasing hormone (GnRH)-pokeweed
1055 antiviral protein conjugates in cell lines expressing GnRH receptors.
1056 Endocrinology 2003, 144 (4), 1456−63.
(16)1057 Erice, A.; Balfour, H. H., Jr.; Myers, D. E.; Leske, V. L.;
1058 Sannerud, K. J.; Kuebelbeck, V.; Irvin, J. D.; Uckun, F. M. Anti-human
1059 immunodeficiency virus type 1 activity of an anti-CD4 immunoconju-
1060 gate containing pokeweed antiviral protein. Antimicrob. Agents
1061 Chemother. 1993, 37 (4), 835−8.
(17)1062 Burchell, J. M.; Mungul, A.; Taylor-Papadimitriou, J. O-linked
1063 glycosylation in the mammary gland: changes that occur during
1064 malignancy. J. Mammary Gland Biol. Neoplasia 2001, 6 (3), 355−64.
(18)1065 Joshi, S.; Kumar, S.; Choudhury, A.; Ponnusamy, M. P.; Batra, S.
1066 K. Altered Mucins (MUC) Trafficking in Benign and Malignant
1067 Conditions. Oncotarget 2014, 5 (17), 7272−84.
(19)1068 Duraisamy, S.; Kufe, T.; Ramasamy, S.; Kufe, D. Evolution of
1069 the human MUC1 oncoprotein. Int. J. Oncol. 2007, 31 (3), 671−7.
(20)1070 Rahn, J. J.; Dabbagh, L.; Pasdar, M.; Hugh, J. C. The importance
1071 of MUC1 cellular localization in patients with breast carcinoma: an
1072 immunohistologic study of 71 patients and review of the literature.
1073 Cancer 2001, 91 (11), 1973−82.
(21)1074 Cheung, K. L.; Graves, C. R.; Robertson, J. F. Tumour marker
1075 measurements in the diagnosis and monitoring of breast cancer.
1076 Cancer Treat. Rev. 2000, 26 (2), 91−102.
(22)1077 Kufe, D. W. Mucins in cancer: function, prognosis and therapy.
1078 Nat. Rev. Cancer 2009, 9 (12), 874−85.
(23) 1079Kagaya, H.; Oba, M.; Miura, Y.; Koyama, H.; Ishii, T.; Shimada,
1080T.; Takato, T.; Kataoka, K.; Miyata, T. Impact of polyplex micelles
1081installed with cyclic RGD peptide as ligand on gene delivery to
1082vascular lesions. Gene Ther. 2012, 19 (1), 61−9.
(24) 1083Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Wang, A. Z.;
1084Langer, R.; Farokhzad, O. C. Nanotechnology and aptamers:
1085applications in drug delivery. Trends Biotechnol. 2008, 26 (8), 442−9.
(25) 1086Ellington, A. D.; Szostak, J. W. In vitro selection of RNA
1087molecules that bind specific ligands. Nature 1990, 346 (6287), 818−
108822.
(26) 1089Tavitian, B. In vivo imaging with oligonucleotides for diagnosis
1090and drug development. Gut 2003, 52 (Suppl 4), iv40−7.
(27) 1091Pieve, C. D.; Perkins, A. C.; Missailidis, S. Anti-MUC1
1092aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7
1093tumour-bearing mice. Nucl. Med. Biol. 2009, 36 (6), 703−10.
(28) 1094Borbas, K. E.; Ferreira, C. S. M.; Perkins, A.; Bruce, J. I.;
1095Missailidis, S. Design and Synthesis of Mono- and Multimeric
1096Targeted Radiopharmaceuticals Based on Novel Cyclen Ligands
1097Coupled to Anti-MUC1 Aptamers for the Diagnostic Imaging and
1098Targeted Radiotherapy of Cancer. Bioconjugate Chem. 2007, 18 (4),
10991205−1212.
(29) 1100Ferreira, C. S.; Cheung, M. C.; Missailidis, S.; Bisland, S.;
1101Gariepy, J. Phototoxic aptamers selectively enter and kill epithelial
1102cancer cells. Nucleic Acids Res. 2009, 37 (3), 866−76.
(30) 1103Kurosaki, T.; Higuchi, N.; Kawakami, S.; Higuchi, Y.;
1104Nakamura, T.; Kitahara, T.; Hashida, M.; Sasaki, H. Self-assemble
1105gene delivery system for molecular targeting using nucleic acid
1106aptamer. Gene 2012, 491 (2), 205−209.
(31) 1107Yin, H.; Kanasty, R. L.; Eltoukhy, A. A.; Vegas, A. J.; Dorkin, J.
1108R.; Anderson, D. G. Non-viral vectors for gene-based therapy. Nat.
1109Rev. Genet. 2014, 15 (8), 541−55.
(32) 1110Midoux, P.; Pichon, C.; Yaouanc, J. J.; Jaffres, P. A. Chemical
1111vectors for gene delivery: a current review on polymers, peptides and
1112lipids containing histidine or imidazole as nucleic acids carriers. Br. J.
1113Pharmacol. 2009, 157 (2), 166−78.
(33) 1114Al-Dosari, M. S.; Gao, X. Nonviral gene delivery: principle,
1115limitations, and recent progress. AAPS J. 2009, 11 (4), 671−81.
(34) 1116Konstan, M. W.; Davis, P. B.; Wagener, J. S.; Hilliard, K. A.;
1117Stern, R. C.; Milgram, L. J.; Kowalczyk, T. H.; Hyatt, S. L.; Fink, T. L.;
1118Gedeon, C. R.; Oette, S. M.; Payne, J. M.; Muhammad, O.; Ziady, A.
1119G.; Moen, R. C.; Cooper, M. J. Compacted DNA nanoparticles
1120administered to the nasal mucosa of cystic fibrosis subjects are safe and
1121demonstrate partial to complete cystic fibrosis transmembrane
1122regulator reconstitution. Hum. Gene Ther. 2004, 15 (12), 1255−69.
(35) 1123Ramamoorth, M.; Narvekar, A. Non viral vectors in gene
1124therapy- an overview. J. Clin Diagn Res. 2015, 9 (1), GE01−6.
(36) 1125Gao, X.; Kim, K. S.; Liu, D. Nonviral gene delivery: what we
1126know and what is next. AAPS J. 2007, 9 (1), E92−104.
(37) 1127Swami, A.; Goyal, R.; Tripathi, S. K.; Singh, N.; Katiyar, N.;
1128Mishra, A. K.; Gupta, K. C. Effect of homobifunctional crosslinkers on
1129nucleic acids delivery ability of PEI nanoparticles. Int. J. Pharm. 2009,
1130374 (1−2), 125−38.
(38) 1131Fischer, D.; Bieber, T.; Li, Y.; Elsasser, H. P.; Kissel, T. A novel
1132non-viral vector for DNA delivery based on low molecular weight,
1133branched polyethylenimine: effect of molecular weight on transfection
1134efficiency and cytotoxicity. Pharm. Res. 1999, 16 (8), 1273−9.
(39) 1135Arias, F. J.; Santos, M.; Fernandez-Colino, A.; Pinedo, G.;
1136Girotti, A. Recent contributions of elastin-like recombinamers to
1137biomedicine and nanotechnology. Curr. Top. Med. Chem. 2014, 14 (6),
1138819−36.
(40) 1139Garcia-Arevalo, C.; Bermejo-Martin, J. F.; Rico, L.; Iglesias, V.;
1140Martin, L.; Rodriguez-Cabello, J. C.; Arias, F. J. Immunomodulatory
1141nanoparticles from elastin-like recombinamers: single-molecules for
1142tuberculosis vaccine development. Mol. Pharmaceutics 2013, 10 (2),
1143586−97.
(41) 1144de Torre, I. G.; Wolf, F.; Santos, M.; Rongen, L.; Alonso, M.;
1145Jockenhoevel, S.; Rodríguez-Cabello, J. C.; Mela, P. Elastin-like
1146recombinamer-covered stents: Towards a fully biocompatible and
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.5b00712
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
M
1147 non-thrombogenic device for cardiovascular diseases. Acta Biomater.
1148 2015, 12 (0), 146.
(42)1149 McDaniel, J. R.; Macewan, S. R.; Dewhirst, M.; Chilkoti, A.
1150 Doxorubicin-conjugated chimeric polypeptide nanoparticles that
1151 respond to mild hyperthermia. J. Controlled Release 2012, 159 (3),
1152 362−7.
(43)1153 Rodriguez-Cabello, J. C.; Piña, M. J.; Ibañ́ez-Fonseca, A.;
1154 Fernandez-Colino, A.; Arias, F. J. Nanotechnological approach to the
1155 therapeutic delivery using elastin-like recombinamers. Bioconjugate
1156 Chem. 2015, 26, 1252.
(44)1157 Urry, D. W. What Sustains Life? Consilient Mechanisms for
1158 Protein-Based Machines and Materials; Springer-Verlag: New York,
1159 2006.
(45)1160 Chen, T. H.; Bae, Y.; Furgeson, D. Y. Intelligent biosynthetic
1161 nanobiomaterials (IBNs) for hyperthermic gene delivery. Pharm. Res.
1162 2008, 25 (3), 683−91.
(46)1163 Piña, M. J.; Alex, S. M.; Arias, F. J.; Santos, M.; Rodriguez-
1164 Cabello, J. C.; Ramesan, R. M.; Sharma, C. P. Elastin-like
1165 recombinamers with acquired functionalities for gene-delivery
1166 applications. J. Biomed. Mater. Res., Part A 2015, 103, 3166.
(47)1167 Shen, W.; van Dongen, M. A.; Han, Y.; Yu, M.; Li, Y.; Liu, G.;
1168 Banaszak Holl, M. M.; Qi, R. The role of caveolin-1 and syndecan-4 in
1169 the internalization of PEGylated PAMAM dendrimer polyplexes into
1170 myoblast and hepatic cells. Eur. J. Pharm. Biopharm. 2014, 88, 658.
(48)1171 Blau, S.; Jubeh, T. T.; Haupt, S. M.; Rubinstein, A. Drug
1172 targeting by surface cationization. Crit. Rev. Ther. Drug Carrier Syst.
1173 2000, 17 (5), 425−65.
(49)1174 Mintzer, M. A.; Simanek, E. E. Nonviral vectors for gene
1175 delivery. Chem. Rev. 2009, 109 (2), 259−302.
(50)1176 Poyet, J.-L.; Hoeveler, A. cDNA cloning and expression of
1177 pokeweed antiviral protein from seeds in Escherichia coli and its
1178 inhibition of protein synthesis in vitro. FEBS Lett. 1997, 406 (1−2),
1179 97−100.
(51)1180 Rodriguez-Cabello, J. C.; Girotti, A.; Ribeiro, A.; Arias, F. J.
1181 Synthesis of genetically engineered protein polymers (recombinamers)
1182 as an example of advanced self-assembled smart materials. Methods
1183 Mol. Biol. 2012, 811, 17−38.
(52)1184 Sallach, R. E.; Cui, W.; Balderrama, F.; Martinez, A. W.; Wen, J.;
1185 Haller, C. A.; Taylor, J. V.; Wright, E. R.; Long, R. C., Jr; Chaikof, E. L.
1186 Long-term biostability of self-assembling protein polymers in the
1187 absence of covalent crosslinking. Biomaterials 2010, 31 (4), 779−791.
(53)1188 Butash, K. A.; Natarajan, P.; Young, A.; Fox, D. K.
1189 Reexamination of the effect of endotoxin on cell proliferation and
1190 transfection efficiency. Biotechniques 2000, 29 (3), 610−4 616, 618−9..
(54)1191 Pinedo-Martín, G.; Castro, E.; Martín, L.; Alonso, M.;
1192 Rodríguez-Cabello, J. C. Effect of Surfactants on the Self-Assembly
1193 of a Model Elastin-like Block Corecombinamer: From Micelles to an
1194 Aqueous Two-Phase System. Langmuir 2014, 30 (12), 3432−3440.
(55)1195 Ren, L.; Marquardt, M. A.; Lech, J. J. Estrogenic effects of
1196 nonylphenol on pS2, ER and MUC1 gene expression in human breast
1197 cancer cells-MCF-7. Chem.-Biol. Interact. 1997, 104 (1), 55−64.
(56)1198 Croce, M. V.; Isla-Larrain, M. T.; Capafons, A.; Price, M. R.;
1199 Segal-Eiras, A. Humoral immune response induced by the protein core
1200 of MUC1 mucin in pregnant and healthy women. Breast Cancer Res.
1201 Treat. 2001, 69 (1), 1−11.
(57)1202 Su, X.; Fricke, J.; Kavanagh, D. G.; Irvine, D. J. In Vitro and in
1203 Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer
1204 Nanoparticles. Mol. Pharmaceutics 2011, 8 (3), 774−787.
(58)1205 Xiao, Z.; Levy-Nissenbaum, E.; Alexis, F.; Luptaḱ, A.; Teply, B.
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